-
公开(公告)号：US20160250276A1
公开(公告)日：2016-09-01
申请号：US15074142
申请日：2016-03-18
Applicant: OSAKA CITY UNIVERSITY
Inventor： Shinji Hirotsune
CPC classification number: A61K38/05 , A61K9/0019 , A61K9/0053 , A61K31/00
Abstract: An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wherein R1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): wherein R4 is lower alkyl, R3 is lower alkylene, and m is an integer of 1 to 6; R2 is lower alkyl optionally substituted with phenyl; and R3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.
Abstract translation: 本发明的一个目的是提供一种用于治疗失精症患者的药物和方法。 本发明提供一种包含由通式（I）表示的化合物的解散性治疗剂或预防剂：其中R 1为被低级烷氧基取代的低级烷基，被杂环基取代的低级烷基，杂环基或由 式（IIa）：其中R 4为低级烷基，R 3为低级亚烷基，m为1至6的整数; R2是任选被苯基取代的低级烷基; 且R 3为任选被卤素，低级烷氧基或苯基取代的低级烷基; 稠合多环烃; 或氢气。
-
12.发明授权公开(公告)号：US09321944B2
公开(公告)日：2016-04-26
申请号：US14122476
申请日：2012-06-01
Applicant: Akikazu Matsumoto , Eriko Sato , Akinori Morino , Koujirou Tanaka
Inventor： Akikazu Matsumoto , Eriko Sato , Akinori Morino , Koujirou Tanaka
IPC: C09J7/00 , C09J133/08 , C09J133/06 , C09J153/00 , C08F293/00 , C08K5/42
CPC classification number: C09J133/08 , C08F293/005 , C08K5/42 , C09J7/00 , C09J7/10 , C09J133/066 , C09J153/005 , C09J2205/102 , C09J2433/00 , C09J2453/00 , C08F2220/1858 , C08F2220/1825 , C08F220/20
Abstract: Suitable adhesive properties and dismantling properties can be obtained, and an interface between an adherent/an adhesive layer or an adhesive layer/a substrate can be suitably dismantlable by the easily dismantlable adhesive composition including an acrylate polymer including a (meth)acrylate monomer having a carboxyl precursor group, 2-ethyl hexyl acrylate, and a monomer having a polar group as a monomer, and an acid catalyst or an acid generator.
Abstract translation: 可以获得合适的粘合性能和拆卸性能，并且粘合剂/粘合剂层或粘合剂层/基材之间的界面可以通过易于拆卸的粘合剂组合物适当地拆卸，所述粘合剂组合物包括含有（甲基）丙烯酸酯单体的丙烯酸酯聚合物， 羧基前体基团，2-乙基己基丙烯酸酯和具有极性基团的单体作为单体，以及酸催化剂或酸发生剂。
-
公开(公告)号：US20150183854A1
公开(公告)日：2015-07-02
申请号：US14403803
申请日：2013-05-30
Applicant: OSAKA CITY UNIVERSITY , TEIJIN PHARMA LIMITED
Inventor： Hiroshi Mori , Takami Tomiyama , Yoichi Matsumoto , Hiroshi Eguchi , Yuichi Kunori
CPC classification number: C07K16/18 , A61K2039/505 , C07K14/4711 , C07K2317/24 , C07K2317/565
Abstract: [SUMMARY][PURPOSE]The invention provides a novel therapeutic agent or prophylactic agent for cognitive disorders.[SOLUTION MEANS]The invention provides an antibody that participates in antigen-antibody reaction specifically with tau protein that has been phosphorylated in the vicinity of Ser413 of SEQ ID NO: 1, and a therapeutic agent or prophylactic agent for cognitive disorders comprising as an active ingredient a peptide that has been phosphorylated in the vicinity of Ser413.
Abstract translation: 发明内容本发明提供了一种用于认知障碍的新型治疗剂或预防剂。 [解决方案]本发明提供参与抗体 - 抗体反应的抗体，特异性地与在SEQ ID NO：1的Ser413附近被磷酸化的tau蛋白，以及包含作为活性的认知障碍的治疗剂或预防剂 成分在Ser413附近被磷酸化的肽。
-
公开(公告)号：US20150011745A1
公开(公告)日：2015-01-08
申请号：US14358509
申请日：2012-11-14
Applicant: Osaka City University
Inventor： Akira Tachibana , Toshizumi Tanabe
IPC: C12N15/113
CPC classification number: C12N15/113 , A61K31/711 , C12N2310/113 , C12N2310/14 , C12N2310/3231 , C12N2310/3519 , C12N2310/50 , C12N2310/531 , C12N2310/533 , C12N2320/30
Abstract: The purpose of the present invention is to develop and provide a nucleic acid molecule that can specifically and efficiently inhibit the activity of a target RNAi molecule and can be produced safely at a low cost. Provided is a nucleic acid molecule for inhibiting the activity of a target RNAi molecule. The nucleic acid molecule comprises a single-stranded nucleic acid moiety that contains one unmodified DNA region composed of a nucleotide sequence completely or sufficiently complementary to a nucleotide sequence of a functional strand having the activity in the target RNAi molecule and a double-stranded nucleic acid moiety to be linked to at least one of the 5′-end and the 3′-end of the single-stranded nucleic acid moiety.
Abstract translation: 本发明的目的是开发和提供能够特异性且有效地抑制靶RNAi分子的活性并可以以低成本安全地制备的核酸分子。 提供了用于抑制靶RNAi分子的活性的核酸分子。 核酸分子包含单链核酸部分，其含有由与靶RNAi分子中具有活性的功能链的核苷酸序列完全或充分互补的核苷酸序列构成的一个未修饰的DNA区域和双链核酸 部分连接到单链核酸部分的5'末端和3'末端中的至少一个。
-
公开(公告)号：US20140315982A1
公开(公告)日：2014-10-23
申请号：US14355711
申请日：2012-11-01
Applicant: OSAKA CITY UNIVERSITY
Inventor： Akira Tachibana , Toshizumi Tanabe
IPC: C12N15/113
CPC classification number: C12N15/113 , A61K31/7105 , C12N15/111 , C12N2310/11 , C12N2310/14 , C12N2310/531 , C12N2320/50 , C12N2320/51
Abstract: Provided are an improved double-stranded nucleic acid molecule involved in gene expression control mediated by a gene silencing mechanism, a method of producing the molecule, and a pharmaceutical composition comprising the double-stranded nucleic acid molecule. The double-stranded nucleic acid molecule for gene expression control comprises an antisense strand having a length of 18 to 28 nucleotides and a sense strand including a complementary moiety composed of a sequence sufficiently complementary to the antisense strand and a protruding single-stranded 5′-end moiety having a length of 2 to 100 nucleotides. The sense strand and the antisense strand form base pairs via the complementary moiety. The method produces such a double-stranded nucleic acid molecule, and the pharmaceutical composition contains such a double-stranded nucleic acid molecule as an active ingredient.
Abstract translation: 提供涉及由基因沉默机制介导的基因表达控制的改进的双链核酸分子，产生该分子的方法和包含双链核酸分子的药物组合物。 用于基因表达控制的双链核酸分子包含长度为18至28个核苷酸的反义链和包含由与反义链足够互补的序列构成的互补部分的有义链和突出的单链5'- 末端部分具有2至100个核苷酸的长度。 有义链和反义链通过互补部分形成碱基对。 该方法产生这样的双链核酸分子，并且该药物组合物含有作为活性成分的这种双链核酸分子。
-
Patent Agency Ranking
16.发明授权公开(公告)号：US08658125B2
公开(公告)日：2014-02-25
申请号：US10277989
申请日：2002-10-23
Applicant: Tsutomu Ohzuku , Hiroshi Yoshizawa , Masatoshi Nagayama
Inventor： Tsutomu Ohzuku , Hiroshi Yoshizawa , Masatoshi Nagayama
CPC classification number: H01M4/505 , H01M4/485 , H01M4/525 , H01M4/661 , H01M10/0525 , H01M10/0562 , H01M2004/021
Abstract: The present invention relates to a positive electrode active material comprising a lithium-containing composite oxide containing nickel with an oxidation state of 2.0 to 2.5 and manganese with an oxidation state of 3.5 to 4.0, the oxidation state determined by the shifts of energy at which absorption maximum is observed in the X-ray absorption near-K-edge structures, and to a non-aqueous electrolyte secondary battery using the same, the positive electrode active material being characterized in having a high capacity, a long storage life and excellent cycle life.
Abstract translation: 本发明涉及一种正极活性物质，其含有氧化态为2.0〜2.5的镍和氧化态为3.5〜4.0的锰的含锂复合氧化物，氧化态由吸收能量的偏移 在X射线吸收近K边缘结构中观察到最大值，并且对于使用其的非水电解质二次电池，正极活性物质的特征在于具有高容量，长存储寿命和优异的循环寿命 。
-
公开(公告)号：US20100087608A1
公开(公告)日：2010-04-08
申请号：US12555247
申请日：2009-09-08
Applicant: Kiyoshi ENDO , Yoshikatsu TSUCHIYA , Makoto OOURA , Hideaki ISHIZU
Inventor： Kiyoshi ENDO , Yoshikatsu TSUCHIYA , Makoto OOURA , Hideaki ISHIZU
IPC: C08F4/42
Abstract: A method that is capable of producing a vinyl chloride-based polymer having excellent thermal stability without sacrificing productivity is provided. The method includes polymerizing a vinyl chloride-based monomer in the presence of a vanadium compound (A) represented by formula: Vi(═O)jZk (wherein i is an integer of 2 to 5, j represents 0 or 1, Z represents a ligand such as is an organic ligand that can bond to the vanadium atom via a hetero atom, and a plurality of ligands Z may be bonded together to form a ring that also includes the vanadium atom as a member of the ring, and k is an integer from 1 to 5), and in the presence of at least one aluminum compound (B).
Abstract translation: 提供能够生产具有优异的热稳定性而不牺牲生产率的氯乙烯类聚合物的方法。 该方法包括在由式（Ⅵ））ZZ表示的钒化合物（A）存在下聚合氯乙烯基单体：其中i为2至5的整数，j表示0或1，Z表示 配体，例如可以通过杂原子键合到钒原子上的有机配体，并且多个配位体Z可以键合在一起形成还包括钒原子作为环的成员的环，k是 1至5的整数）和至少一种铝化合物（B）的存在下进行。
-
18.发明申请公开(公告)号：US20080096111A1
公开(公告)日：2008-04-24
申请号：US11976491
申请日：2007-10-25
Applicant: Tsutomu Ohzuku , Hiroshi Yoshizawa , Masatoshi Nagayama
Inventor： Tsutomu Ohzuku , Hiroshi Yoshizawa , Masatoshi Nagayama
CPC classification number: H01M4/525 , H01M2/34 , H01M4/0471 , H01M4/13 , H01M4/362 , H01M4/485 , H01M4/505 , H01M10/052 , H01M10/0525 , H01M10/42 , H01M2004/021 , H01M2004/028 , H01M2010/4292
Abstract: The present invention provides a high-capacity and low-cost non-aqueous electrolyte secondary battery, comprising: a negative electrode containing, as a negative electrode active material, a substance capable of absorbing/desorbing lithium ions and/or metal lithium; a separator; a positive electrode; and an electrolyte, wherein the positive electrode active material contained in the positive electrode is composed of crystalline particles of an oxide containing two kinds of transition metal elements, the crystalline particles having a layered crystal structure, and oxygen atoms constituting the oxide forming a cubic closest packing structure.
Abstract translation: 本发明提供一种高容量，低成本的非水电解质二次电池，其特征在于，包括：负极，含有能够吸收/解吸锂离子和/或金属锂的物质作为负极活性物质; 分隔符 正极; 以及电解质，其中正极中所含的正极活性物质由含有两种过渡金属元素的氧化物的晶体颗粒构成，结晶粒子具有层状晶体结构，构成氧化物的氧原子形成立方最近 包装结构。
-
公开(公告)号：US20070009424A1
公开(公告)日：2007-01-11
申请号：US11531887
申请日：2006-09-14
Applicant: Tsutomu Ohzuku , Hiroshi Yoshizawa , Masatoshi Nagayama
Inventor： Tsutomu Ohzuku , Hiroshi Yoshizawa , Masatoshi Nagayama
CPC classification number: H01M4/1391 , B01J19/1875 , B01J19/1881 , C01B13/363 , C01G45/1228 , C01G51/42 , C01G51/50 , C01G53/42 , C01G53/50 , C01P2002/20 , C01P2002/50 , C01P2002/52 , C01P2002/54 , C01P2002/72 , C01P2004/61 , C01P2006/40 , H01M4/505 , H01M4/525 , Y10T29/49108
Abstract: A positive electrode active material for a non-aqueous electrolyte battery comprising a lithium-containing transition metal oxide, produced with the use of a dry precursor obtained by: introducing an alkaline solution together with an aqueous solution containing two or more of transition metal salts or two kinds or more of aqueous solutions of different transition metal salts into a reaction vessel to obtain a hydroxide or an oxide as a precursor through coprecipitation with a reductant being coexistent or an inert gas being supplied; and drying the precursor at 300 to 500° C. to obtain a dry precursor.
Abstract translation: 一种非水电解质电池用正极活性物质，其特征在于，含有含锂过渡金属氧化物，其使用干燥前体制造，所述干燥前体通过：将碱性溶液与含有两种以上过渡金属盐的水溶液 两种或更多种不同过渡金属盐的水溶液进入反应容器，以通过共存的还原剂或供应的惰性气体通过共沉淀获得氢氧化物或氧化物作为前体; 并在300〜500℃下干燥前体，得到干燥前体。
-
公开(公告)号：US10750988B2
公开(公告)日：2020-08-25
申请号：US16270794
申请日：2019-02-08
Applicant: OMRON HEALTHCARE Co., Ltd. , OSAKA CITY UNIVERSITY
Inventor： Kenji Fujii , Shingo Yamashita , Yasuyoshi Watanabe , Kei Mizuno
IPC: A61B5/00 , A61B5/16 , A61B5/0245 , A61B5/024
Abstract: A fatigue degree determination device includes a fatigue degree determination unit. A first biological heart rate is acquired while a user is awake and at rest, based on a biological heart rate measured from the user. A second biological heart rate is acquired while the user is sleeping, based on the biological heart rate measured from the user. The fatigue degree determination unit determines a fatigue degree of the user, based on information read out from a storage medium, the first biological heart rate and the second biological heart rate. The storage medium stores the information in which a degree of change of one biological heart rate relative to the other biological heart rate of a biological heart rate while a person is awake and at rest and a biological heart rate while the person is sleeping and a fatigue degree are associated with each other.
-
-
-
-
-
-
-
-
-
Search Results
90
records
(took 0.035 seconds)
